Saturday 17 October 2026
Export NBP’s income statement to Excel — free account
NovaBridge Biosciences
In the quarter to June 2026, EPS fell 123.3% and free cash flow grew 34.3%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
1.26
0.03
−2.33%
Follow NBP
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 9.30 | 41.18 | 3.19 | 1.16 | 0.84 | 0.60 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 47.46 | 85.40 | 47.75 | 7.67 | 2.54 | 6.79 | |||||
| People | |||||||||||||||
| People | Employees | — | — | 185 | 185 | 228 | 378 | 318 | 220 | 32 | 30 | ||||
| Revenue/emp, $m | — | 0.00 | 0.04 | 0.02 | 1.04 | 0.04 | (0.10) | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | 2 | 8 | 4 | 236 | 14 | — | 1 | — | — | ||||
| Gross margin, % | — | 0.00 | 0.00 | 100.00 | 100.00 | 47.25 | 112.29 | 100.00 | — | — | |||||
| EBT | — | (44) | (61) | (209) | 74 | (366) | (363) | (82) | (50) | (88) | |||||
| EBT margin, % | — | (2,580.85) | (745.82) | (4,840.10) | 31.32 | (2,652.32) | 1,131.32 | (13,009.02) | 0.00 | 0.00 | |||||
| Net income | — | 0 | 0 | (209) | 72 | (366) | (364) | (82) | (50) | (88) | |||||
| Depreciation | — | 0 | 1 | 2 | 4 | 5 | 9 | 1 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | 0.03 | 0.14 | 1.34 | 4.05 | 0.18 | (0.39) | 0.01 | 0.00 | 0.00 | ||||
| Earnings | — | (0.33) | (1.05) | (64.99) | 1.24 | (4.82) | (4.24) | (2.33) | (0.27) | (0.48) | |||||
| Cash flow | — | (0.64) | (0.73) | (38.85) | 1.14 | (2.01) | (1.94) | (0.87) | (0.65) | (0.22) | |||||
| Capex | — | 0.00 | 0.00 | (0.55) | (0.02) | (0.06) | (0.08) | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | (0.64) | (0.73) | (39.40) | 1.12 | (2.07) | (2.02) | (0.88) | (0.65) | (0.21) | |||||
| Book value | — | (0.79) | (2.39) | 59.43 | 14.78 | 9.42 | 5.11 | 2.91 | 2.48 | 2.41 | |||||
| Shares, m | — | 58 | 58 | 3 | 58 | 76 | 83 | 83 | 81 | 96 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | ||||
| P/S | — | 6.19 | 6.19 | 6.19 | 16.47 | 15.05 | 1.37 | 9.73 | — | — | |||||
| P/B | — | 0.23 | 0.23 | 0.23 | 4.52 | 5.19 | 0.83 | 0.78 | — | — | |||||
| EV/Sales | — | (16.57) | (16.57) | (16.57) | 13.42 | 12.39 | (0.60) | (5.58) | — | — | |||||
| EV/FCF | — | 0.00 | 0.00 | 0.00 | (19.50) | (12.69) | 0.33 | 0.25 | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | (37) | (42) | (125) | 66 | (153) | (160) | (73) | (53) | (21) | ||||
| Capex | — | (3) | (2) | (2) | (1) | (5) | (7) | 0 | 0 | 0 | |||||
| Free cash flow | — | (37) | (42) | (126) | 65 | (157) | (167) | (73) | (53) | (21) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | 76 | 246 | 148 | 731 | 652 | 416 | 272 | 168 | 191 | ||||
| Total debt | — | 142 | 446 | 17 | 1 | 5 | 3 | 4 | — | — | |||||
| Net debt | — | 38 | 170 | (159) | (733) | (666) | (511) | (312) | (173) | (211) | |||||
| Shareholders’ equity | — | (46) | (139) | 191 | 862 | 715 | 422 | 243 | 201 | 231 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | (17.53) | 0.00 | (170.93) | 11.83 | (39.56) | (49.47) | (43.30) | (7.64) | (19.56) | ||||
| ROIC | — | 0.00 | 0.00 | (415.21) | 11.51 | (413.03) | 0.00 | 0.00 | (115.77) | (293.14) | |||||
| ROE | — | 47.67 | 65.76 | (826.99) | 13.71 | (46.37) | (63.92) | (62.52) | (10.02) | (21.42) | |||||
Negative figures in brackets.
value withheld pending a data check
Fiscal years to Dec 2023 · latest quarter Sep 2023 · fundamentals updated 1 Oct 2026
Charts ten years each
NovaBridge Biosciences vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ADAG Adagene Inc. Sponsored ADR | $161.1M | — (loss-making) | — (loss-making) | — | — | −11.08% (below 0%: shrinking) | — | — | Compare |
| MDWD MediWound Ltd. | $157.6M | — (loss-making) | — (loss-making) | −45.83% (below 0%: shrinking) | n/m | −49.90% (below 0%: shrinking) | 10.90% | (305.89%) | Compare |
| NBP NovaBridge Biosciences | $149.6M | — (loss-making) | — (loss-making) | −88.54% (below 0%: shrinking) | n/m | +34.25% (above 0%: growing) | 100.00% | 0.00% | |
| CNTN Canton Strategic Holdings, Inc. | $149.0M | 9.0× | — | — | n/m | −600.39% (below 0%: shrinking) | 100.00% | (80.37%) | Compare |
| CDXS Codexis, Inc. | $148.9M | — (loss-making) | — (loss-making) | −2.69% (below 0%: shrinking) | n/m | +48.60% (above 0%: growing) | 76.45% | (75.29%) | Compare |
| MENS Jyong Biotech Ltd. | $147.0M | — | — | — | — | — | — | — | Compare |
| MSLE Satellos Bioscience Inc. | $145.1M | — (loss-making) | — | — | n/m | −65.66% (below 0%: shrinking) | 99.26% | 0.00% | Compare |
| MOLN Molecular Partners AG Sponsored ADR | $143.5M | — (loss-making) | — (loss-making) | −98.86% (below 0%: shrinking) | n/m | +23.77% (above 0%: growing) | 0.00% | 0.00% | Compare |
| TARA Protara Therapeutics, Inc. | $141.8M | — (loss-making) | — | — | n/m | −28.10% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $148.0M | — | — | −45.83% | — | −28.10% | 43.67% | (37.64%) |
NovaBridge Biosciences (NBP) key facts
- NovaBridge Biosciences (NBP) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
- As of October 16, 2026, NBP traded at $1.26, a market capitalization of $149.6 million.
- Return on equity was −21.4% and debt-to-equity 0.00.
- Its Altman Z-score is −3.80 (distress zone) for fiscal 2023.
NovaBridge Biosciences (NBP) Latest News
No news at this impact. Lower the threshold for more.